Hua Medicine taps Hong Kong for biotech flotation

By John Loh
07 Jun 2018

Hua Medicine has filed for an IPO in Hong Kong under sponsors CLSA and Goldman Sachs, as the promised pipeline of biotechnology issuers begins to materialise following the city’s new listing rules.

China-based Hua is developing an oral drug to treat type 2 diabetes, the company said in the draft prospectus. It is conducting phase three trials in China for its flagship drug, Dorzagliatin.

China has the world’s largest population of type 2 diabetes patients with 120m people diagnosed with the ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial